Formulierungen und verfahren zur steuerung der mdi-partikelgrössenfreisetzung

Formulations and methods for controlling mdi particle size delivery

Formulations et procédés de commande de distribution granulométrique mdi

Patent Citations (61)

    Publication numberPublication dateAssigneeTitle
    US-2003147814-A1August 07, 20033M Innovative Properties CompanyMedicinal aerosol formulations comprising ion pair complexes
    US-6315985-B1November 13, 20013M Innovative Properties CompanyC-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
    US-7018618-B2March 28, 2006Chiesi Farmaceutici S.P.A.Stable pharmaceutical solution formulations for pressurized metered dose inhalers
    WO-9947505-A1September 23, 1999Byk Gulden Lomberg Chemische Fabrik GmbhPhthalazinone pde iii/iv inhibitors
    WO-03082827-A1October 09, 2003Schering AktiengesellschaftDerives de quinoleine et d'isoquinoleine, procede de production de ces derives et leur utilisation comme agents anti-inflammatoires
    US-2005267145-A1December 01, 2005Merrill Bryon A, Myrdal Paul B, Wightman Paul DTreatment for lung cancer
    US-5552438-ASeptember 03, 1996Smithkline Beecham CorporationCompounds useful for treating allergic and inflammatory diseases
    WO-9534534-A1December 21, 1995The Wellcome Foundation LimitedEnzyme inhibitors
    WO-2004018429-A2March 04, 2004Boehringer Ingelheim Pharmaceuticals, Inc.Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
    WO-2004009017-A2January 29, 2004Bristol-Myers Squibb CompanyModulateurs de recepteurs de glucocorticoides et procede associe
    WO-9965464-A1December 23, 1999Boehringer Ingelheim Pharmaceuticals, Inc.Preparations pharmaceutiques pour aerosols a deux principes actifs ou plus
    US-6451285-B2September 17, 2002Baker Norton Pharmaceuticals, Inc.Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
    WO-02066422-A1August 29, 2002Glaxo Group LimitedPhenethanolamine derivatives for treatment of respiratory diseases
    WO-03091204-A1November 06, 2003Glaxo Group LimitedPhenethanolamine derivatives
    WO-2004039766-A1May 13, 2004Glaxo Group LimitedDerives de phenylethanolamine pour le traitement de maladies respiratoires
    WO-0110143-A1February 08, 2001Motorola, Inc.Method and apparatus in a wireless communication system for creating a learning function
    US-6716414-B2April 06, 2004Chiesi Farmaceutici S.P.A.Stable pharmaceutical solution formulations for pressurized metered dose inhalers
    US-5676930-AOctober 14, 1997Boehringer Ingelheim Pharmaceuticals, Inc.Stabilized medicinal aerosol solution formulations
    WO-9313055-A1July 08, 1993The Wellcome Foundation LimitedAmidino derivatives and their use as nitric oxide synthase inhibitors
    WO-2004022547-A1March 18, 2004Glaxo Group LimitedPhenethanolamine derivatives and their use in the treatment of respiratory diseases
    WO-9916766-A1April 08, 1999Kyowa Hakko Kogyo Co., Ltd.Benzodioxole derivatives
    WO-2004009016-A2January 29, 2004Bristol-Myers Squibb CompanyCompositions et procedes impliquant le site ii des recepteurs nucleaires d'hormones (nhr)
    WO-2004016578-A2February 26, 2004Glaxo Group LimitedArylethanolamine beta2-adrenoreceptor agonist compounds
    WO-03072539-A1September 04, 2003Glaxo Group LimitedDerives de phenethanolamine pour traiter des maladies respiratoires
    WO-0202565-A2January 10, 2002Abbott Laboratories, Ligand Pharmaceuticals IncorporatedAgents anti-inflammatoires a selectivite glucocortiocoide
    WO-0116128-A1March 08, 2001Abbott LaboratoriesDibenzopyranes utiles en tant qu'antagonistes du recepteur des glucocorticoides, dans le traitement du diabete
    WO-2004037807-A2May 06, 2004Glaxo Group LimitedMedicinal arylethanolamine compounds
    US-5776433-AJuly 07, 1998Minnesota Mining And Manufacturing CompanyFlunisolide aerosol formulations
    WO-2004026248-A2April 01, 2004Merck & Co., Inc.Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
    WO-2009095681-A2August 06, 2009Vectura Limited, Innovata Biomed Limited, Whitfield, Nicola, KimSuspension formulations
    WO-03008277-A2January 30, 2003Riverwood International CorporationCarton d'emballage dote d'un dispositif de distribution ameliore combine a une seule poignee
    WO-2004024728-A2March 25, 2004Glaxo Group LimitedPyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
    WO-03086294-A2October 23, 2003Merck & Co., Inc.Derives de 1h-benzo[f]indazol-5-yl utilises en tant que modulateurs selectifs du recepteur glucocorticoide
    WO-03082787-A1October 09, 2003Boehringer Ingelheim Pharmaceuticals, Inc.Mimetiques du glucocorticoide, procedes de fabrication de ces mimetiques, compositions pharmaceutiques et leurs utilisations
    US-6004537-ADecember 21, 1999Baker Norton Pharmaceuticals, Inc.Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
    WO-0250021-A1June 27, 2002Glaxo Group LimitedSel phosphate inhibiteur d'oxyde nitrique synthase
    WO-2004037773-A1May 06, 2004Glaxo Group LimitedDerive de phenethanolamine utilise dans le traitement de maladies respiratoires
    US-2004081627-A1April 29, 2004Jinks Phillip A, Mckenzie Lesley, Lister James T.Medicinal aerosol formulations
    WO-03059899-A1July 24, 2003Boehringer Ingelheim Pharmaceuticals, Inc.Mimetiques de glucocorticoides, procedes de fabrication, preparations pharmaceutiques renfermant ces mimetiques et utilisations
    WO-9830537-A1July 16, 1998Glaxo Group LimitedNitric oxide synthase inhibitors
    WO-03042160-A1May 22, 2003Theravance, Inc.Agonistes de recepteur d'aryl aniline beta-2 adrenergique
    US-7601336-B2October 13, 2009Chiesi Farmaceutici S.P.A.Pharmaceutical aerosol composition
    WO-03082280-A1October 09, 2003Boehringer Ingelheim Pharmaceuticals, Inc.Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    WO-2004037768-A2May 06, 2004Glaxo Group LimitedPhenethanolamine derivatives
    US-6045778-AApril 04, 2000Boehringer Ingelheim Pharmaceuticals, Inc.Stabilized medicinal aerosol solution formulations
    WO-02070490-A1September 12, 2002Glaxo Group LimitedAgonistes de beta-adrenocepteurs
    US-6290930-B1September 18, 2001Baker Norton Pharmaceuticals, Inc.Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
    WO-9854159-A1December 03, 1998Schering AktiengesellschaftNon-steroidal (hetero) cyclically substituted acylanilides with mixed gestagen and androgen activity
    WO-0226722-A1April 04, 2002Glaxo Group LimitedMorpholin-acetamide derivatives for the treatment of inflammatory diseases
    WO-03104195-A1December 18, 2003Boehringer Ingelheim Pharmaceuticals, Inc.4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
    WO-2004039762-A1May 13, 2004Glaxo Group LimitedDerives de phenethanolamine permettant de traiter des maladies des voies respiratoires
    WO-03024439-A1March 27, 2003Glaxo Group LimitedDerives de phenethanolamine destines au traitement de maladies respiratoires
    WO-9962875-A1December 09, 1999Glaxo Group LimitedNitric oxide synthase inhibitors
    WO-0142193-A1June 14, 2001Theravance, Inc.Agonistes des recepteurs adrenergiques du beta 2
    WO-03061651-A1July 31, 2003The Regents Of The University Of CaliforniaNon-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
    WO-0066590-A2November 09, 2000Ligand Pharmaceuticals, Inc., American Home Products CorporationComposes modulateurs de recepteur de progesterone tetracycliques et procedes
    WO-03101932-A2December 11, 2003Boehringer Ingelheim Pharmaceuticals, Inc.Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    US-2003152521-A1August 14, 20033M Innovative Properties CompanyMedicinal aerosol compositions with a functionalized polyethyleneglycol excipient
    WO-2004005229-A1January 15, 2004Pfizer Products Inc.Modulateurs du recepteur glucocorticoide
    WO-02076933-A1October 03, 2002Glaxo Group LimitedFormailide derivatives as beta2-adrenoreceptor agonists
    WO-03086349-A1October 23, 20033M Innovative Properties CompanyFormulations d'aerosol de formoterol et de ciclesonide

NO-Patent Citations (5)

    Title
    HOFGEN, N. ET AL., 15TH EFMC HIT SYMP MED CHERN, pages 98
    JOHNSON, M.: "Inhaled corticosteroid -long-acting b2-agonist synergism: therapeutic implications in human lung disease", PROCEEDINGS OF RESPIRATORY DRUG DELIVERY, vol. IX, 2004, pages 99 - 108
    LANDELLS, L.J. ET AL., EUR RESP J [ANNU CONG EUR RESP SOC (SEPT 19-23, GENEVA) 1998, vol. 12, no. 28, 1998, pages 2393
    STEIN, S.W., AAPSPHARMSCITECH, vol. 19, 2008, pages 112 - 115
    TANABE SEIYAKU; FUJI, K. ET AL., J PHARMACOL EXP THER, vol. 284, no. 1, 1998, pages 162

Cited By (0)

    Publication numberPublication dateAssigneeTitle